NeOnc Technologies (NTHI)

The company’s pipeline targets intracranial malignancies, including gliomas, glioblastoma, and meningioma. These cancers are difficult to treat because of their location, aggressive biology, and limited surgical or drug-based options for many patients. NeOnc’s strategy is to use molecular delivery approaches that may improve how therapeutic compounds reach cancer cells in the brain while seeking to reduce systemic exposure.

Its lead candidates include NEO100 and NEO212. NEO100 is being developed as an intranasal therapy for brain cancer patients, using the nasal route as a potential way to deliver treatment toward the central nervous system. NEO212 is an oral chemical conjugate designed for glioblastoma, combining therapeutic concepts intended to enhance activity against tumor cells. As with other clinical-stage biotechnology companies, NeOnc’s value is closely tied to trial progress, safety and efficacy data, regulatory outcomes, and its ability to finance continued research.

NeOnc operates in a specialized and high-risk area of medicine where unmet need remains significant. Glioblastoma in particular has historically had poor outcomes and few durable treatment advances. The company’s distinctive focus is not only on new drug candidates, but also on delivery mechanisms that aim to overcome one of the central obstacles in treating brain tumors.